SLC18A3

Chr 10AR

solute carrier family 18 member A3

Also known as: CMS21, VACHT

The encoded protein is a vesicular acetylcholine transporter that uses a proton gradient to transport acetylcholine into synaptic vesicles for neurotransmitter release at cholinergic synapses. Biallelic mutations cause congenital myasthenic syndrome type 21, a presynaptic neuromuscular transmission disorder inherited in an autosomal recessive pattern. This gene has moderate constraint against loss-of-function variants (LOEUF 0.636), suggesting some tolerance to complete protein loss.

Summary from RefSeq, OMIM, UniProt
Research Assistant →

Primary Disease Associations & Inheritance

Myasthenic syndrome, congenital, 21, presynapticMIM #617239
AR
0
Active trials
4
Pubs (1 yr)
63
P/LP submissions
2%
P/LP missense
0.64
LOEUF
Multiple*
Mechanism· predicted
Clinical SummarySLC18A3
Population Constraint (gnomAD)
Constrained for loss-of-function variants (OE-LoF 0.20) despite low pLI — interpret in context.
📋
ClinVar Variants
62 unique Pathogenic / Likely Pathogenic· 220 VUS of 400 total submissions
📖
GeneReview available — SLC18A3
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.64LOEUF
pLI 0.454
Z-score 2.33
OE 0.20 (0.080.64)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
0.15Z-score
OE missense 0.98 (0.891.07)
311 obs / 318.3 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.20 (0.080.64)
00.351.4
Missense OE0.98 (0.891.07)
00.61.4
Synonymous OE1.27
01.21.6
LoF obs/exp: 2 / 9.9Missense obs/exp: 311 / 318.3Syn Z: -2.63
DN
0.6939th %ile
GOF
0.75top 25%
LOF
0.3357th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

400 submitted variants in ClinVar

Classification Summary

Pathogenic38
Likely Pathogenic24
VUS220
Likely Benign100
Benign11
Conflicting6
38
Pathogenic
24
Likely Pathogenic
220
VUS
100
Likely Benign
11
Benign
6
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
38
0
38
Likely Pathogenic
1
1
22
0
24
VUS
2
178
34
6
220
Likely Benign
0
5
0
95
100
Benign
0
3
1
7
11
Conflicting
6
Total318795108399

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

SLC18A3 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →